Writing For Biotech Industry

𝗜𝗘𝗖 𝟲𝟮𝟰𝟰𝟯 𝗶𝘀 𝗻𝗼𝘁 𝗷𝘂𝘀𝘁 𝗮 𝘀𝗲𝗿𝗶𝗲𝘀 — 𝗶𝘁’𝘀 𝗮 𝗳𝗮𝗺𝗶𝗹𝘆 𝗼𝗳 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁 𝗱𝗼𝗰𝘂𝗺𝗲𝗻𝘁 𝘁𝘆𝗽𝗲𝘀. 𝗔𝗻𝗱 𝗲𝗮𝗰𝗵 𝘀𝗲𝗿𝘃𝗲𝘀 𝗮 𝗽𝘂𝗿𝗽𝗼𝘀𝗲. When people say “IEC 62443 compliance,” they often miss an important nuance: not all documents in the series carry the same weight or intent. Understanding the document types helps teams interpret requirements correctly and avoid treating guidance as mandatory controls. 𝗧𝗵𝗲 𝗺𝗮𝗶𝗻 𝗱𝗼𝗰𝘂𝗺𝗲𝗻𝘁 𝘁𝘆𝗽𝗲𝘀 𝗶𝗻 𝗜𝗘𝗖 𝟲𝟮𝟰𝟰𝟯 • IS — International Standard The normative requirements. These define what must be met for compliance or certification. 👉 Example: technical and process requirements • TS — Technical Specification Detailed technical requirements or methods where full consensus may still be evolving. 👉 Often more implementation-focused • TR — Technical Report Informational guidance, background, or explanatory material. 👉 Helps interpretation but is not normative • PAS — Publicly Available Specification Early guidance published quickly to address emerging needs. 👉 May later evolve into TS or IS 𝗪𝗵𝘆 𝘁𝗵𝗶𝘀 𝗺𝗮𝘁𝘁𝗲𝗿𝘀 Many teams mistakenly treat every document as mandatory — which leads to confusion and unnecessary complexity. In reality: 👉 IS defines requirements 👉 TS provides technical depth 👉 TR explains context 👉 PAS captures emerging practices Knowing the difference helps you build a roadmap that is both compliant and practical. #IEC62443 #OTSecurity #IndustrialCybersecurity #ICS #CyberResilience #Standards #SecurityFramework #CriticalInfrastructure

If you’re working in MedTech QA or Regulatory Affairs, you know the drill: labeling and IFUs are usually the last things on the checklist, yet they are often the first thing auditors tear apart. With the release of the 2nd edition, the bar for global compliance just got higher. I’ve been diving deep into the new requirements to see how they impact our technical documentation and QMS. I’ve put together a presentation demo breaking down the 2026 changes, but I wanted to share a few "from the trenches" takeaways that you won't find in the table of contents: The "Applicable Policy" Clause is a Game Changer: The 2026 version introduces more formal flexibility to align with regional authorities (like the EMA or FDA) without clashing with the ISO standard. For those of us managing global portfolios or transitioning borderline products, this is the clarity we’ve been waiting for. The 14971 "Handshake": I see this mistake constantly—treating the IFU as a marketing document. Under the new standard, labeling is a primary risk control measure. Every warning and contraindication in your IFU must have a direct, documented link to your Risk Management File. If that link is broken, your compliance is broken. V&V and Production Identifiers: The 2026 edition sharpens the definitions for lot codes and batch numbers. If your Design V&V Traceability Matrix hasn’t been updated to reflect these specific identifiers, you’re leaving a gap for auditors to find. Traceability is about the correct nomenclature, not just having the data. Digital is the Default: The emphasis on eIFUs and website accessibility has increased. Your digital infrastructure must be built for the entire lifetime of the device, not just the launch phase. Version control for digital labeling is no longer optional; it’s a core requirement. I’ve mapped out this standard and how to practically apply in a new presentation demo. If you’d like a copy to share with your team or use for internal training, just drop a comment below and I’ll share it. I’m curious to hear from other QA/RA leads, what’s the biggest labeling hurdle you’re anticipating with the move to the 2026 edition? #MedicalDevices #ISO20417 #QualityAssurance #RegulatoryAffairs #EUMDR #MedTech #ISO13485 #RiskManagement #QAQC

🧩 Technical Standards every MedTech professionals should know! Whether you're dealing with a Class I device, Class III or building an AI-based SaMD, aligning with the right standards is critical for regulatory success and product quality. But where do you start? Which ones are essential for your compliance? Of course, specific standards depend on device type, intended use, and market. But today I decided to share those standards that form the foundation of regulatory expectations across the industry. 👇 Here's a selection of technical standards every MedTech or regulatory team should be aware of, with recent updates and what’s coming!   🛡️ 𝗚𝗲𝗻𝗲𝗿𝗮𝗹 𝘀𝗮𝗳𝗲𝘁𝘆 𝗮𝗻𝗱 𝗾𝘂𝗮𝗹𝗶𝘁𝘆 📌 ISO 13485 Medical Devices - Quality Management Systems 📌 ISO 14971 Medical Devices - Risk Management 📌 IEC 62366-1 Medical Devices - Usability Engineering 📌 ISO 10993 series Biological Evaluation for Medical Devices 📌 IEC 60601 Series Electrical Safety Requirements 📌 ISO 15223-1 Medical Devices - Labelling 💻 𝗦𝗼𝗳𝘁𝘄𝗮𝗿𝗲, 𝗜𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗦𝗲𝗰𝘂𝗿𝗶𝘁𝘆 𝗮𝗻𝗱 𝗔𝗜 📌 IEC 62304 Software Life Cycle Processes 📌 ISO 27001 Information Security Management Systems 📌 ISO 42001 Information technology - Artificial intelligence - Management system 🧪 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗜𝗻𝘃𝗲𝘀𝘁𝗶𝗴𝗮𝘁𝗶𝗼𝗻, 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗣𝗲𝗿𝗳𝗼𝗿𝗺𝗮𝗻𝗰𝗲 𝗦𝘁𝘂𝗱𝗶𝗲𝘀 📌 ISO 14155 Medical Devices - Clinical Investigations 📌 ISO 20916 IVDs – Clinical performance studies 📣📣 What’s New: 📘 ISO 14155:2026 → Clinical investigation of medical devices for human subjects — Good clinical practice → Edition 4, 2026 published in March. 📘 ISO 10993-7:2026 → Biological evaluation of medical devices Part 7: Ethylene oxide sterilization residuals → Edition 3, 2026 just published. 📘 ISO 20417:2026 → Medical devices - Information to be supplied by the manufacturer → 2026 Edition published, and 2021 officially withdrawn. 📣 What’s Coming: 📘 ISO 18969 → A new standard for clinical evaluation of medical devices → Under development, now in Draft International Standard (DIS) stage. ⚠️ Staying up to date and monitor standards stage is not just good practice, it's essential to ensure compliance as expectations evolve.   New versions may change what's acceptable in risk management, testing, documentation, and more. This is why, on the MedBoard platform regulatory intelligence is not just about regulations and guidance. 👉 Real-time monitoring includes standards updates, adoptions, and country recognitions. So teams can stay informed, all in one place.   💬 Which of these do you use most?   #MedBoard #MedTech #MedicalDevices #RegulatoryAffairs #QualityManagement #RiskManagement  #ClinicalEvaluation #Compliance #ISO13485 #ISO14971 #MDSW #ClinicalAffairs #PostMarketSurveillance

Regulatory standards change constantly. Missing one update can trigger audit findings. The solution isn’t checking websites randomly. It’s building a monitoring system that works. Here’s the monitoring rhythm that keeps you compliant: Check Weekly: • FDA guidance documents • EU MDR/IVDR updates • MDCG guidance papers These change frequently and impact your compliance immediately. Check Monthly: • PMDA requirements (Japan) • ANVISA regulations (Brazil) • TGA standards (Australia) Regional updates affect your market access in those territories. Check Quarterly: • ISO 13485 amendments • ISO 14971 revisions • IEC 62304 updates • IEC 60601 changes Standard revisions require QMS overhauls and procedure updates. Monitoring alone won’t protect you. You need to convert findings into action. 1. Define clear ownership → Regulatory Affairs monitors changes → Quality assesses the impact → Product teams implement updates 2. Document your monitoring activities → Maintain a monitoring log in your QMS → Record review dates and decisions → Auditors will request this evidence 3. Update procedures quickly → Revise SOPs within 30 days → Schedule training immediately → Update risk management files 4. Track harmonization status → Verify which standards are harmonized in EU → Check FDA recognition status → This determines your presumption of conformity Common gaps that create findings: • No documented monitoring process • Informal tracking without QMS integration • Changes identified but not implemented • No cross-functional communication • Missing regional requirements A proper monitoring system requires: • Defined review frequencies • Multiple information sources • Clear role assignments • Impact assessment process • Documentation trail The difference between companies that pass audits and those that don’t? The first group knows about regulatory changes before auditors ask. The second group learns about them during the audit. Your monitoring system determines which group you join. ⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡ MedTech regulatory challenges can be complex, but smart strategies, cutting-edge tools, and expert insights can make all the difference. I'm Tibor, passionate about leveraging AI to transform how regulatory processes are automated and managed. Let's connect and collaborate to streamline regulatory work for everyone! #automation #regulatoryaffairs #medicaldevices

Just validate the software!  Sounds simple but at a medical device company there are many types of software that need to be validated and the rules and requirements are different for each type. I put together this diagram of the “software landscape” to help people understand what type of software they’re working with. The diagram shows all the categories and sub-categories of software at a medical device company with examples of each type. First, we divide the landscape into product software and “non-product software.” Product software, if it’s regulated, falls under FDA design control regulations and international standards for medical device development such as IEC 62304. Product software includes all the software you develop plus any third party software included in your product. Within the regulated product software category there are three sub-categories based on the safety risk of the software (classes A / B / C per the IEC 62304 medical software standard). The fourth category “Enforcement Discretion” refers to low risk applications that are technically regulated by FDA but for which FDA has decided not to enforce regulations. On the non-product software side different regulations and standards apply and therefore different requirements for validation and documentation. There are three main sub-categories of non-product software: software used in manufacturing, software used in product development, and software used in the quality system. These can vary considerably in complexity and risk profile, including everything from an Excel spreadsheet to a software test script to a very complex PLM system. The testing and documentation required for validation of non-product software depends very much on the risks associated with them and their complexity (i.e. a one-size-fits-all approach to validation will either over-validate or under-validate the wide variety of non-product software). My recommendation is to follow the FDA guidance for “Computer Software Assurance for Production and Quality System Software” and the international guidance ISO/TR 80002-2:2017 “Validation of software for medical device quality systems.” See links in the comments below. Do you have any tips for managing the variety of regulated software at a medical device company? What has worked well (or badly) at your company? #medicaldevices #medicalsoftware #samd

🌍 CMC Harmonization Challenges in Global Biologic Submissions As biologics continue to expand globally, the harmonization of CMC (Chemistry, Manufacturing, and Controls) data across regulatory regions remains one of the most complex aspects of drug development. Even with the common CTD (Common Technical Document) format, true harmonization between regulatory agencies like the FDA, EMA, and other global authorities is far from seamless. Here are some of the key challenges that CMC teams face 👇 🔹 1. Differing Data Expectations While the CTD structure aligns globally, the depth and timing of CMC data differ — FDA allows progressive build-up (fit-for-phase), whereas EMA and other agencies expect more comprehensive datasets even for early-phase trials. 🔹 2. Variability in Process Validation and GMP Requirements FDA typically accepts validation data later in development, but many regions require detailed validation summaries or GMP certificates upfront. This creates timing conflicts and documentation rework for global submissions. 🔹 3. Divergent Stability and Shelf-life Expectations Regulators differ in the amount of stability data required to support clinical supply — leading to country-specific protocols, shelf-life justifications, and additional bridging studies. 🔹 4. Managing Post-Approval Changes Globally Lifecycle management (e.g., comparability, tech transfers, or scale-up) becomes challenging when each region interprets variation classifications differently. A single change may trigger multiple submission types across jurisdictions. 🔹 5. Communication and Alignment Across Cross-functional Teams CMC harmonization requires tight collaboration among Regulatory, QA, Manufacturing, and Analytical teams — yet regional nuances often lead to misalignment in documentation, terminology, or data presentation. 💡 The Path Forward: To overcome these hurdles, forward-looking organizations are: Building global CMC master files with modular data adaptable per region. Engaging in early regulatory dialogue (FDA Type C, EMA Scientific Advice). Investing in Regulatory Intelligence and CMC data management systems to ensure consistency across submissions.

Is your GMP system collapsing under the weight of its own paperwork? If documentation is slowing you down more than it’s protecting patients, you’re not alone. It started with a deviation. Just a 5-minute delay in a mixing step. By the time it was closed, the team had created: 📄 47 pages of documentation 📚 9 cross-referenced SOPs 🧾 3 levels of review 🧠 A “lessons learned” log… for a low-impacting issue ✅ Every line: accurate. ✅ Every reviewer: diligent. ✅ Every link: cited. So why did the site fail its FDA inspection 3 months later? ⚠️ Because investigators couldn’t find the signal through the noise. ⸻ Over-documentation ≠ good documentation It feels safe to “cover all bases,” but it can backfire: • Reviewer fatigue • Delayed investigations • System inconsistencies • Missed critical info ⸻ 🌍 Expectations vary by region: 🇺🇸 FDA wants “adequate,” “contemporaneous,” and “complete” , not everything. 🇪🇺 EMA under Annex 1 stresses control + traceability, but favors lean. 🇬🇧 MHRA prioritizes clarity and risk-driven documentation. 🇯🇵 PMDA often prefers detailed redundancy, but still value-driven. 💡 No regulator asks for everything. They ask for what matters. ⸻ 📌 5 ways to escape the over-doc trap: 1️⃣ Use Risk-Based Thinking Apply ICH Q9 to scale based on impact. 2️⃣ Tier Documentation Group by: • Critical-to-Quality • Regulatory-Mandated • Operational Reference 3️⃣ Involve End-Users Early Ask: “What helps?” and “What slows us down?” 4️⃣ Digitize with Intent Don’t digitize chaos. Design smart, searchable systems. 5️⃣ Define Your Philosophy Set a documentation mission. Review it yearly. ⸻ 📣 Bottom line: From ICH Q10 to FDA’s quality maturity model—the signal is clear: ✨ Documentation should enable decisions, not bury them. — 🗣️ Your turn: Have you seen documentation slow down compliance? What helped you fix it? Let’s trade ideas. Because in GMP… Clarity is compliance. ♻️ Repost to increase awareness of your teams. #GMP #QualityCulture #RiskBasedApproach #GMPDocumentation #ComplianceLeadership #ICHQ10 #FDA #EMA #MHRA #PMDA #DigitalQMS #Biotech #PharmaManufacturing #RightFirstTime #QualityByDesign

In regulated industries, if it isn’t documented, it didn’t happen. 📝 Good Documentation Practice (GDocP) isn’t just about neat handwriting or filing protocols — It’s a critical foundation for compliance, data integrity, and audit readiness. Here’s what GDocP truly means: 🔹 What is GDocP? It’s the standard for creating, completing, and managing controlled documents — ensuring every action in production, commissioning, validation, and manufacturing is traceable and credible. 🔹 When does GDocP apply? Anytime you prepare, complete, review, file, archive, or dispose of controlled documents. (In other words: always.) 🔹 Principles of GDocP: ✅ Clear, accurate, and timely entries ✅ Permanent and legible records ✅ Truthful and complete documentation ✅ Standardized formats (dates, times, units) 🔹 Critical Dos and Don’ts: ✅ Sign only with authorized signatures (log them properly) ✅ Record data at the time of action (never before, never after) ✅ Fill every blank space (use N/A, N/R if needed) ✅ Correct errors with a single line, initial, and date 🚫 Never erase, overwrite, use whiteout, or leave blanks 🔹 Good documents are: Permanent. Legible. Accurate. Prompt. Clear. Consistent. Complete. Truthful. 💡 GDocP isn't bureaucracy. It's trust on paper — and without trust, there’s no compliance. Save this as a reminder for yourself, your team, or your next project kickoff. Mastering GDP isn’t just good practice — it’s the heart of regulatory success. 🔵 #GDP #GoodDocumentationPractice #Validation #GMPCompliance #DataIntegrity #CQV #QualityAssurance #LifeSciences #Pharma #Biotech #AuditReadiness

FDA just finalized its human factors engineering guidance on May 29, 2026 — and it changes how medical device companies justify usability submissions. The big shift: a new Decision Point D in the submission flowchart means that even devices with new or impacted critical tasks may no longer automatically require full HF validation testing. Here's what quality and regulatory teams need to know: Three risk-based HF Submission Categories (1, 2, and 3) now structure every marketing submission — and category selection appears directly in eSTAR templates, making HF a front-and-center element of every device review. Decision Point D evaluates user interface use history, UI complexity, and adequacy of existing risk controls. A robust justification supported by a comprehensive Use-Related Risk Analysis can now substitute for a new summative usability study — in the right circumstances. Existing HF data can be leveraged across submissions. Prior HF content does not need to be resubmitted — cross-references are acceptable. This rewards companies with well-organized, traceable HFE documentation. The HFE/UE report outline has changed. Sections 5 and 6 are transposed — update your templates before the next submission. One critical compliance note: FDA has signaled that HF records may be requested during QMSR inspections — even for Category 1 and 2 devices. That means documentation must exist regardless of submission category. FDA is holding a Town Hall on July 22, 2026 to discuss the guidance. Registration details pending from FDA. For medical device quality teams, the message is clear: human factors documentation is no longer a submission-stage exercise. It belongs in your Design and Development File from day one of development.